Wolff J M, Ting O, Borchers H, Rohde D, Jakse G
Department of Urology, University of Rostock, 18055 Rostock, Germany.
Anticancer Res. 2000 Nov-Dec;20(6D):5191-3.
The measurement of prostate specific antigen (PSA) is widely used for the early detection of prostate cancer. However the influence of renal failure on the serum levels of the PSA molecular forms is still a matter of investigation. We therefore examined the serum concentration of total and free PSA in patients undergoing hemodialysis and discuss the influence of renal failure on both types.
Serum concentrations of total PSA, free PSA and the free-to-total PSA ratio were measured in 48 men undergoing hemodialysis. Total and free PSA levels were measured employing a chemiluminescent enzyme immunoassay.
Serum levels of total PSA, free PSA as well as the free-to-total PSA ratio did not change significantly in uremic patients after hemodialysis. Median total PSA concentration was 1.1 ng/mL before and 1.15 ng/mL after hemodialysis (p = 0.24); median free PSA concentration was 0.29 ng/mL before and 0.32 ng/mL after hemodialysis (p = 0.14). Median free-to-total PSA ratio was 0.29 ng/mL before and 0.31 ng/mL after hemodialysis (p = 0.66).
Serum free PSA as well as total PSA is not eliminated by hemodialysis and the slightly elevated levels of free PSA and the free-to-total PSA ratio in uremic patients after hemodialysis may be caused by the concomitant decrease in binding proteins. We therefore conclude that the reference ranges for total PSA, free PSA and the f-/t-PSA ratio are applicable undergoing chronic hemodialysis.
前列腺特异性抗原(PSA)的检测广泛用于前列腺癌的早期检测。然而,肾衰竭对PSA分子形式血清水平的影响仍是一个研究课题。因此,我们检测了接受血液透析患者的总PSA和游离PSA的血清浓度,并探讨肾衰竭对这两种类型PSA的影响。
检测了48例接受血液透析男性患者的总PSA、游离PSA血清浓度以及游离PSA与总PSA的比值。采用化学发光酶免疫分析法检测总PSA和游离PSA水平。
血液透析后尿毒症患者的总PSA、游离PSA血清水平以及游离PSA与总PSA的比值均无显著变化。血液透析前总PSA浓度中位数为1.1 ng/mL,透析后为1.15 ng/mL(p = 0.24);游离PSA浓度中位数透析前为0.29 ng/mL,透析后为0.32 ng/mL(p = 0.14)。游离PSA与总PSA比值中位数透析前为0.29 ng/mL,透析后为0.31 ng/mL(p = 0.66)。
血液透析不能清除血清游离PSA和总PSA,尿毒症患者血液透析后游离PSA水平及游离PSA与总PSA比值略有升高可能是由于结合蛋白同时减少所致。因此,我们得出结论,总PSA、游离PSA及f-/t-PSA比值的参考范围适用于慢性血液透析患者。